Drugs and treatments group Alliance Pharma plc (LON:APH) has been growing through its 'buy and build' strategy for 17 years but its acquisition of the healthcare products business from Sinclair Pharma late in 2015 puts the group in a different league.
It doubles the scale of sales and profits and takes its supply of medicines and products to over 100 countries, from 40 previously.
To underline the point, the £132mln Sinclair acquisition - the largest of 31 deals to date - took effect from December 17 and in the few days from then until the end of the year, it contributed £0.8mln to group sales.
It adds to the group 27 products, which generated annual revenues in the year to June 2015 of £43.3mln, and have already generated revenues of £30.5mln for the first four months of 2016, which was in line with board's expectations.
In its latest stock market offering the group said: "The key activity of combining the two organisations is underway. We are in the process of integrating the Sinclair products under the Alliance name and of aligning the operational capabilities of the enlarged company; both projects are progressing to plan."
So what are Alliance's main products?
No single brand accounts for around 9% of total sales.
The portfolio has two product types - those with growth potential that are actively managed and invested in, prescription or consumer, and what's called a "bedrock" of brands already well established in their market niches and will provides sales for many years with little or no promotion.
From the Sinclair acquisition, Alliance has gained four key growth products.
Three of these, Kelo-cote, Flammazine/ Flammacerium and AtopiclairTM are in skincare and wound management, while the other, AloclairTM, is an over-the-counter treatment for mouth ulcers.
It is worth noting that Kelo-Cote, a scar reduction product, is now the group's largest-selling brand. Its sales of £3mln in the first four months of 2016 were in line with forecast.
Meanwhile, Hydromol - the dermatological range - which includes an ezcema cream, comes from the group's original portfolio.
Hydromol showed good growth in 2015, achieving year on year sales growth of 10% to £6.6mln and has seen sales rise by 7% over the first three months of 2016 compared to the same period in 2015.
Anbesol, one of its consumer health products, an area in which it is expanding, for teething and ulcers, saw sales grow 20% to £1.5mln, while Gelclair, a treatment for oral mucositis, rose 5% to £1.4mln.
Elsewhere, multivitamin and mineral Forceval capsules saw sales in 2015 up by £0.6mln to £2.1mln.
Elsewhere, Macushield for the eye condition macular degeneration, acquired in February last year, contributed £3.5mln in sales in 2015.
The group also owns the lip balm brand Lypsyl, whose sales were flat last year at £1.1mln while it works on redesigning the product for relaunch in 2016.
In the mother and child business, Diclectin, which the group has in-licensed for the UK market, is on track to be the only licensed product for nausea and vomiting of pregnancy.
Group results for 2015
Underlying pre- tax profit was up 6% at £11.4mln (2014:£10.8mln) on revenue up 11% to £48.3mln (2014:43.5mln).
The proposed final dividend was up 10% to 0.734p a share against 0.667p a share in 2014. Adjusted diluted EPS (earnings per share) was at £3.61p (2014: 3.34p).
So what's on the cards for 2016?
The firm expects the enlarged group will perform in line with expectations for the full year.
"Although most of the one-off costs of the Sinclair acquisition were met in 2015, we expect the bulk of the integration costs to be borne in 2016.
"We also intend to take the opportunity to invest in a significant new enterprise resource planning (ERP) system over the next 18 months," chief executive John Dawson said in full year results in April.